Zydus Lifesciences Ltd.

Zydus Lifesciences has informed that it enclosed a copy of press release dated May 28, 2025, titled ‘Zydus receives USFDA ‘Fast Track Designation’ for Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of Amyotrophic Lateral Sclerosis (ALS)’. The contents of the press release give full details. 

The above information is a part of company’s filings submitted to BSE.